Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have been assigned a consensus rating of “Hold” from the eight research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.20.

MRTX has been the subject of several research reports. Zacks Investment Research upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Wednesday, May 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $5.50 target price on shares of Mirati Therapeutics in a research report on Wednesday, April 12th. Finally, ValuEngine upgraded Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Broadfin Capital LLC boosted its position in shares of Mirati Therapeutics by 153.1% in the first quarter. Broadfin Capital LLC now owns 2,090,801 shares of the biotechnology company’s stock valued at $10,872,000 after buying an additional 1,264,800 shares during the last quarter. Aviva Holdings Ltd. boosted its position in shares of Mirati Therapeutics by 44.6% in the first quarter. Aviva Holdings Ltd. now owns 2,880,702 shares of the biotechnology company’s stock valued at $14,980,000 after buying an additional 888,617 shares during the last quarter. Boxer Capital LLC boosted its position in shares of Mirati Therapeutics by 37.0% in the first quarter. Boxer Capital LLC now owns 1,037,994 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 280,059 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Mirati Therapeutics during the first quarter valued at $854,000. Finally, Sabby Management LLC boosted its position in shares of Mirati Therapeutics by 150.4% in the first quarter. Sabby Management LLC now owns 249,735 shares of the biotechnology company’s stock valued at $1,299,000 after buying an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 64.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/07/analysts-set-mirati-therapeutics-inc-mrtx-target-price-at-8-10.html.

Mirati Therapeutics (NASDAQ:MRTX) traded down 1.04% during midday trading on Friday, hitting $4.75. The stock had a trading volume of 56,939 shares. The company has a 50-day moving average price of $4.02 and a 200-day moving average price of $4.54. The company’s market cap is $118.46 million. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $7.22.

Mirati Therapeutics Company Profile

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.